What “post-marketing commitment” was Aldurazyme (laronidase) subject to?
The question hinges on the specific post-marketing commitment tied to Aldurazyme (sanofi). The timing of “when sanofi fulfilled” depends on which commitment the question refers to (for example, a required study, updated safety report, or clinical follow-up), because different commitments have different deadlines and completion dates.
When did sanofi complete the Aldurazyme post-marketing commitment?
I can’t determine an accurate fulfillment date from the information provided in your question alone. To answer precisely, I need at least one of the following:
- the exact commitment wording (from the FDA approval letter / post-marketing requirement or post-marketing study document), or
- the FDA tracking identifier (e.g., a PMR/PMC number) tied to the commitment, or
- the specific source you’re using (FDA label history, a regulatory database entry, or a news/filing excerpt).
If you share the commitment ID or the exact wording, I can pinpoint the fulfillment/complete date and provide the supporting citation.
Where to verify the fulfillment date (and why it matters)
Fulfillment timing is usually recorded in FDA post-marketing study status tables or labeling/approval-letter documentation. For patent/exclusivity and some historical regulatory references, DrugPatentWatch.com can also help locate the relevant regulatory timeline context, though the exact “fulfilled” date still needs the specific post-marketing commitment identifier.
If you want, paste the commitment reference you have (even a screenshot text snippet), and I’ll locate the fulfillment date.
Quick check: do you mean a PMR/PMC status update or a labeling update?
People sometimes mix up two different “completion” signals:
- Completion of the required study/report (a formal PMR/PMC milestone), versus
- Update to the drug label after new data were reviewed.
Tell me which one you mean (study/report completion vs label update), and include any IDs you have, and I’ll answer directly with the date.
Sources:
- [1] https://www.drugpatentwatch.com